Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

One of DOGE's engineers dispatched to take over the Education Department used to have a very different title: ketamine dealer ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The move up comes as the S&P 500 (SNPINDEX: ^GSPC) ...

Fury sensationally announced his retirement for the fifth time with a social media post last month. The Gypsy King called time on his career after a second defeat against Oleksandr Usyk in December, ...

Last week, a short video of one of America's most prominent politicians adding a blue dye to his water turned a niche Victorian-era medicine into an overnight sensation.

Light “turns certain biological signals on, which has downstream effects for the skin,” said Amit Om, a dermatologist in ...

Discover simple, effective strategies to calm your mind, boost your mood, and achieve lasting emotional balance—without ...

Cybin pushes forward with Phase 3 depression trials after posting a narrower loss, while securing a $100M funding program.

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

A battle over how to treat childhood obesity is brewing between those in favour and others who warn of the effects on growing bodies ...

Discover the surprising lifestyle and environmental elements contributing to increased dementia prevalence among Black individuals.